

**ASX Release**

**Oventus receives \$1.039M 2017 Government R&D Cash Rebate**

Brisbane, Australia 1<sup>st</sup> of November 2018: Oventus Medical Ltd (ASX: OVN) is pleased to announce that it has received a cash refund of \$1,039,988 from the Australian Taxation Office under the Federal Government's Research and Development (R&D) Tax Incentive scheme.

The refund is from Oventus' financial year 2018 research activities and reflects a significant period of investment into Oventus' O<sub>2</sub>Vent range of oral appliances for the treatment of obstructive sleep apnoea.

CEO, Chris Hart commented, "It's important for companies like ours to have the support of the Federal Government while commercialising our technology. The R&D tax incentive is a tremendous source of non-dilutive funding for Oventus and we are grateful to receive this cash injection as a result of the investments we have made into the development of our new and much needed treatment option for sleep apnoea patients."

—ENDS—

For more information, please contact:

Dr Chris Hart, Managing Director and CEO: M: 0409647496

Jane Lowe, IR Department: M: 0411 117 774 or [jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)

**About Oventus**

Oventus is a Brisbane, Australia, based medical device company that has commercialized and brought to market a new **sleep treatment platform** for the treatment of sleep apnoea and snoring that enhances the treatment outcomes of both oral appliance therapy and CPAP therapy through increased efficacy and greater adherence.

**Oral appliance:** Oventus' unique and patented 'Airway Technology' incorporated into an oral appliance, the O<sub>2</sub>Vent™, bypasses multiple levels of breathing obstruction including the nose, soft palate and tongue.

Our appliances are particularly designed for sufferers with nasal obstructions, soft palate collapse and who consequently tend to breathe through their mouth while sleeping.

In action, when nasal obstruction is present, breathing is supplemented through the O<sub>2</sub>Vent™'s integrated 'Airways' delivering air to the back of the mouth while maintaining an oral seal, stabilizing the tongue base, bypassing obstructions in the nose and soft palate and reducing the collapsibility of

the upper airway. However, when the nose is unobstructed, the O<sub>2</sub>Vent™ allows for natural nasal breathing.

**‘O<sub>2</sub>Vent™ Connect’ Positive Airway Pressure (PAP) Connection:** Severe sleep apnoea sufferers who have traditionally used a CPAP machine and full facemask can use Oventus’ O<sub>2</sub>Vent™ oral appliance to interface with CPAP reducing operating pressure by around 66%, eliminating the need for straps and allowing physiologic mouth breathing while delivering CPAP. This has allowed for a re-design of the CPAP delivery system which is far less intrusive (without full face mask and straps), called the ‘O<sub>2</sub>Vent™ Connect’.

Oventus’ O<sub>2</sub>Vent™ Connect’ attaches to the front of the O<sub>2</sub>Vent™, thereby doing away with the full face mask, while bringing air from the CPAP machine to the nasal opening at lower pressure.

**Clinical trials:** Over 50 patients to date have shown Oventus’ O<sub>2</sub>Vent™ is successful in treating Obstructive Sleep Apnoea (OSA) by an additional 30-50% and that snoring was either eliminated or significantly reduced, when compared to mandibular or “jaw” advancement oral appliances which primarily reduce tongue based breathing obstruction. The positive results included those sufferers who had nasal obstructions and mainly breath through the mouth.

**Market:** According to a report published by the Sleep Health Foundation Australia, an estimated 1.5 million Australians suffer with sleep disorders and more than half of these suffer with obstructive sleep apnoea.<sup>1</sup>

Continuous positive airway pressure (CPAP) is the most definitive medical therapy for obstructive sleep apnoea, however many patients have difficulty tolerating CPAP<sup>2</sup> due to discomfort caused from high operating pressure and low tolerance for a full face mask.

**The Oventus oral appliance ‘Airway Technology’ in the O<sub>2</sub>Vent™ when incorporated with Oventus’ ‘O<sub>2</sub>Vent™ Connect’ allows sufferers to breathe physiologically through the mouth or through the nose whilst simultaneously delivering CPAP. Mild sufferers are able to solely wear the O<sub>2</sub>Vent™ oral appliance.**

Further information can be found on our website: <http://oventus.com.au/how-it-works/>.

<sup>1</sup> Deloitte Access Economics. *Reawakening Australia: the economic cost of sleep disorders in Australia*, 2010. Canberra, Australia.

<sup>2</sup> Beecroft, et al. *Oral continuous positive airway pressure for sleep apnea; effectiveness, patient preference, and adherence*. *Chest* 124:2200–2208, 2003.